Pfizer shows Covid-19 Vaccine is more than 90% Effective

Shookt! Pfizer’s experimental COVID-19 vaccine appears to be working. The vaccine was found to be more than 90% effective, be good 2020! be good!…

On Monday, November 9, The drug maker Pfizer announced that an early analysis of its coronavirus vaccine trial suggested the vaccine was robustly 90% effective in preventing Covid-19, a promising development as the world has waited anxiously for any positive news about a pandemic that has killed more than 1.2 million people.

Pfizer, which developed the vaccine with the German drugmaker BioNTech, released only sparse details from its ongoing Phase 3 trials, it comes from an interim analysis of a study involving 43,538 volunteers, 42% of whom had “diverse backgrounds”.

Protection in patients was achieved seven days after the second of two doses, and 28 days after the first, according to preliminary findings.

The company said that the analysis found from the vaccine was more than 90 percent effective in preventing the disease among trial volunteers who had no evidence of prior coronavirus infection. If the results hold up, that level of protection would put it on par with highly effective childhood vaccines for diseases such as measles. No serious safety concerns have been observed, the company said.

UPDATE: We are proud to announce, along with @BioNTech_Group, that our mRNA-based #vaccine candidate has, at an interim analysis, demonstrated initial evidence of efficacy against #COVID19 in participants without prior evidence of SARS-CoV-2 infection.

— Pfizer Inc. (@pfizer) November 9, 2020

“The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19”, Pfizer chairman and CEO Albert Bourla said in a statement.

We are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis.

‘We are reaching this critical milestone in our vaccine development program at a time when the world needs it most”, Bourla added.

Pfizer plans to ask the Food and Drug Administration for emergency authorization of the two-dose vaccine later this month, after it has collected the recommended two months of safety data. By the end of the year it will have manufactured enough doses to immunize 15 million to 20 million people, company executives have said.